Here are 1-3 brief analogies for Danaher (DHR):

• Like a **Berkshire Hathaway** focused on acquiring, integrating, and growing a portfolio of leading scientific and diagnostic technology companies.
• A highly specialized and diversified **3M** or **Honeywell**, but primarily serving the life sciences, diagnostics, and environmental sectors with critical high-tech tools and solutions.

• Life Sciences Research Tools: Provides instruments, consumables, and software used in scientific research, drug discovery, and bioprocessing applications.
• Clinical Diagnostics: Offers systems and consumables for the diagnosis of diseases and monitoring of treatments in medical laboratories and hospitals.
• Water Quality Solutions: Delivers instruments, disinfection systems, and related consumables for analyzing and treating water in municipal, industrial, and residential settings.
• Product Identification Technologies: Supplies coding, marking, and labeling equipment, along with consumables and software, for a wide range of industries.

Danaher (DHR) primarily sells to other companies and organizations (B2B/B2G) rather than directly to individuals. Due to its diversified portfolio across life sciences, diagnostics, and environmental & applied solutions, Danaher serves a very broad customer base. It does not typically have individual "major customers" (i.e., specific named companies) that account for a significant portion of its overall revenue and are publicly disclosed in its financial filings.

Instead, Danaher serves the following major categories of customers:

1. Healthcare Providers and Diagnostic Laboratories: This category includes hospitals, clinics, reference laboratories, blood banks, and physician offices that utilize Danaher's diagnostic instruments, reagents, and services for disease detection, monitoring, and treatment guidance.

2. Biopharmaceutical Companies and Research Institutions: This includes pharmaceutical companies, biotechnology firms, contract research organizations (CROs), academic institutions (universities), and government research laboratories. These customers use Danaher's life sciences tools, consumables, and services for drug discovery and development, basic research, and bioproduction.

3. Industrial, Manufacturing, and Environmental Facilities: This category encompasses a wide range of customers including industrial manufacturers, food and beverage producers, packaging and printing companies, municipal water treatment facilities, industrial wastewater treatment facilities, and environmental monitoring agencies. They use Danaher's solutions for water quality analysis, product identification, and process control.

null

Rainer M. Blair, President and Chief Executive Officer

Rainer M. Blair has served as President and Chief Executive Officer of Danaher since September 2020. He joined Danaher in 2010, holding various leadership roles before becoming Executive Vice President of Danaher's Life Sciences platform in 2017. Prior to joining Danaher, Mr. Blair was President and CEO of MAPEI Americas and held leadership positions with BASF Group across three continents.

Matthew R. McGrew, Executive Vice President and Chief Financial Officer

Matthew R. McGrew has been the Executive Vice President and Chief Financial Officer of Danaher since January 2019. He joined Danaher in April 2004 and has held positions of increasing responsibility within Internal Audit, M&A, and served as Vice President of Investor Relations. Before his tenure at Danaher, Mr. McGrew was a Director in the Transactions Services Group at KPMG.

Jose-Carlos Gutierrez-Ramos, Senior Vice President and Chief Scientific Officer

Dr. Jose-Carlos Gutierrez-Ramos has served as Senior Vice President and Chief Scientific Officer since joining Danaher in December 2020. Prior to Danaher, he served as Vice President of Global Drug Discovery at AbbVie Inc. and as President and Chief Executive Officer of biotechnology companies Repertoire Immune Medicines and Synlogic, Inc.

Julie Sawyer Montgomery, Executive Vice President, Danaher Diagnostics Platform

Julie Sawyer Montgomery serves as the Executive Vice President of Danaher's Diagnostics Platform. She is a key leader responsible for one of Danaher's diverse segments.

Greg Milosevich, Executive Vice President, Life Sciences

Greg Milosevich holds the position of Executive Vice President, Life Sciences at Danaher. He is responsible for a significant platform within the company.

Danaher Corporation (DHR) operates primarily in the Life Sciences and Diagnostics segments. The Environmental & Applied Solutions segment was spun off into an independent public company named Veralto in the fourth quarter of 2023.

Life Sciences Segment

• Bioprocessing: The global large and small-scale bioprocessing market size was estimated at USD 80.75 billion in 2024 and is projected to reach approximately USD 248.12 billion by 2034. The global bioprocessing market is also expected to reach a value of US$ 72.55 billion by 2031, growing from US$ 25.35 billion in 2023.
• Genomics: The global genomics market was valued at US$42.4 billion in 2023, stood at US$42.6 billion in 2024, and is projected to advance to US$66.8 billion by 2029. Another estimate indicates the global genomics market size was valued at USD 32.65 billion in 2023 and is projected to reach USD 94.86 billion by 2030.
• Life Science Instrumentation: The global life science instrumentation market was valued at US$54.9 billion in 2023 and is projected to reach US$73.9 billion by 2028.

Diagnostics Segment

• Pathology (Laboratories & Services): The global pathology laboratories market size was calculated at USD 380.9 billion in 2024 and is projected to reach around USD 836.15 billion by 2034. The global pathology services market is forecast to reach USD 36 billion by 2035, up from USD 18.8 billion in 2025.
• Digital Pathology: The global digital pathology market was valued at US$1.30 billion in 2024 and is projected to reach US$2.75 billion by 2030.
• Molecular Diagnostics/DNA Diagnostics: The global DNA diagnostics market is valued at an estimated USD 13.3 billion in 2024 and is projected to reach USD 21.2 billion by 2029.

Former Environmental & Applied Solutions Segment (now Veralto)

This segment was spun off from Danaher in Q4 2023 to form Veralto Corporation. However, for historical context and as a former part of Danaher's portfolio, here are some market sizes for its components:

• Water Quality Testing & Analysis: The global water testing & analysis market is projected to grow from USD 26.2 billion in 2025 to USD 51.0 billion by 2035. The global water testing market is valued at USD 4.59 billion in 2025 and is expected to reach USD 6.02 billion by 2030.
• Product Identification: null

Danaher (DHR) is anticipated to experience future revenue growth over the next 2-3 years, driven by several key factors:

1. Sustained Demand in Bioprocessing: The increasing global production of biological medicines, particularly monoclonal antibodies, is expected to continue driving significant revenue within Danaher's Biotechnology segment. This area has demonstrated consistent momentum and is a primary growth driver for the company.
2. Recovery and Innovation in Diagnostics: The Diagnostics segment is projected to achieve higher growth as policy headwinds in China gradually abate. This growth is further supported by new product introductions, such as the DxC 500i integrated chemistry and immunoassay analyzer, and the expansion of the installed base for clinical diagnostics globally, outside of China.
3. Consistent Growth from Recurring Revenue (Consumables and Services): A substantial portion of Danaher's revenue, approximately 80%, is derived from consumables and services. This high proportion of recurring revenue provides a stable and growing base across its Life Sciences and Diagnostics businesses, ensuring strong cash flows and consistent performance.
4. Strategic Acquisitions and Portfolio Management: Danaher's ongoing strategy involves disciplined capital deployment and strategic acquisitions to enhance its portfolio. This transformation over the past several years has created a focused life sciences and diagnostics innovator, positioning the company for higher long-term growth and market leadership by expanding into attractive sectors.

Share Repurchases

• In 2024, Danaher executed a $4.5 billion share buyback, representing the largest in the company's history.
• A new share repurchase program was approved in July 2024, authorizing the repurchase of up to an additional 20 million shares.
• In Q2 2025, Danaher repurchased $5.98 billion worth of common stock. A new program was also authorized in September 2025 for up to 35 million shares.

Share Issuance

• In May 2020, Danaher commenced concurrent offerings of $1.25 billion of common stock and $1.25 billion of Series B Mandatory Convertible Preferred Stock.
• The Series B Mandatory Convertible Preferred Stock converted into 8.6 million shares of Danaher's common stock on April 17, 2023.
• Shares outstanding have shown minor fluctuations, with a 0.81% increase in 2023 and a 0.79% decline in 2024.

Outbound Investments

• Danaher acquired GE Healthcare's Biopharma business (now Cytiva) for $21.4 billion in March 2020.
• In August 2021, Danaher acquired Aldevron, which produces mRNA and proteins, for $9.6 billion in cash.
• In December 2023, Danaher acquired Abcam for approximately $5.7 billion.

Capital Expenditures

• Danaher's capital expenditures averaged $1.185 billion from fiscal years 2020 to 2024, peaking at $1.392 billion in December 2024.
• Capex nearly doubled over the past five years, from $791 million in 2020 to $1.39 billion in 2024, indicating high capital requirements.
• Capital expenditures are primarily focused on the acquisition of property, plant, and equipment to expand operations, accelerate core growth at acquired companies, and support research and development. Expected capital expenditures for 2025 are $1.244 billion, increasing to $1.392 billion by 2027.